Development and comparison of three Zr- 89-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study

Hu, GL; Zhu, WJ; Liu, Y; Wang, Y; Zhang, Z; Zhu, SK; Duan, WW; Zhou, PP; Fu, C; Li, F; Huo, L

Li, F; Huo, L (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Ctr Rare Dis Res,Beijing Key Lab Mol Targeted Dia, Dept Nucl Med,State Key Lab Complex Severe & Rare, 1 Shuaifuyuan, Beijing 100730, Peoples R China.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022; 49 (8): 2634